lymphomas

Over 60 international experts in T-cell lymphoma met in Montevideo, Uruguay, on 12–13 April 2018 to discuss the launch of the new T-cell Project 2.0. ... Due to changes in the WHO classification for T-cell lymphomas in 2016, Prof Federico stated in the meeting report “it is necessary to update the current ...

The EZH2 inhibitor is being studied as a monotherapy in ongoing Phase I and II programs in molecularly defined solid tumors, including epithelioid sarcoma and other INI1-negative tumors; both follicular lymphoma and diffuse large B-cell lymphoma forms of NHL; mesothelioma; and combination studies in ...

Two Children's Oncology Group studies suggest progress has been made in the treatment of and survival outcomes for children and adolescents with Hodgkin lymphoma. Kara M. Kelly, MD, the Waldemar J. Kaminski endowed chair of pediatrics at Roswell Park Comprehensive Cancer Center, directed ...

The investigational EZH2 inhibitor tazemetostat was safe and shrank tumors in 38 percent of patients with relapsed or refractory B-cell non-Hodgkin's lymphoma who were included in the first part of a Phase 1/2 clinical trial, the therapy's developer, Epizyme, announced. The study (NCT01897571) ...

However, a day after the four-hour surgery, Miller's doctors changed their diagnosis from a spinal infection to Burkitt Lymphoma. So far, as doctors are waiting for the advice of oncologists regarding the next steps for her treatment, Miller is said to be recovering well, although she may still need additional ...

“We now have brentuximab vedotin (Adcetris) approved in the frontline setting for Hodgkin lymphoma, which brings up the question on everyone's mind of what the preferred regimen for patients with advanced-stage Hodgkin lymphoma is,” Moskowitz said in a presentation at the 2018 OncLive® State of the ...

However, the particular form of non-Hodgkin's lymphoma that Miller appears to have is aggressive, meaning it grows quickly, Michael Jain, M.D., Ph.D., a hematologist with Moffitt Cancer Center, tells SELF. In cases of Burkitt lymphoma, it's possible for someone to have sudden, excruciating pain, he says.

Owen O'Connor, MD, PhD, director of the Center for Lymphoid Malignancies at New York-Presbyterian Hospital, discusses the possibility of using chimeric antigen receptor (CAR) T-cell therapies for the treatment of patients with mantle cell lymphoma (MCL). This can be tricky for a number of reasons, but ...

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses the use of CDK 4/6 inhibitors in mantle cell lymphoma (MCL). Chen-Kiang says that targeting tumor cells in lymphoid malignancies offers a unique advantage over solid tumors, as the cells can be purified ...

Patients with peripheral T-cell lymphomas receiving standard treatment have worse outcomes if they are not responsive to first-line therapy, a prospective study shows. Bone marrow transplants undertaken after these therapies have failed, however, can significantly increase the survival rates of these ...

Michot called FL the most important histology treated in this study of B-cell non-Hodgkin lymphomas. The objective response rate (ORR) was 77% for patients with FL or marginal zone lymphoma (MZL). Twelve patients (40%) with FL had a complete response (CR) and 11 (37%) had a partial response (PR); ...

Treatment for Hodgkin and non-Hodgkin lymphomas also differs, and survival rates do too. Hodgkin lymphoma is typically considered to be more treatable, and more than 90% of patient survive more than five years after their diagnosis. NHL survival rates are usually lower. “There are so many different ...

April 19, 2018. In a major step toward improving treatment for lymphoma, researchers have published information that suggests genetic sub-types of the disease can be identified and used to help doctors tailor treatments to individual patients. The study, published April 12, 2018 in the New England Journal of Medicine, was ...

The most common type of lymphoma is diffuse large B-cell lymphoma (DLBCL), accounting for about 1 in 3 lymphomas, and approximately half of these tumors are resistant to chemo-immunotherapy. Once the lymphoma originates in a lymphoid tissue, cell proliferation causes rupture of the tissue's overall ...

The background: The National Cancer Institute and other organizations have been studying for about 2 decades the effect of DNA mutations in a patient's tumors on their response to lymphoma treatments, according to study author Louis Staudt of the lymphoid malignancies branch of the NCI's Center for ...

Hodgkin lymphoma (HL) is a B-cell driven hematological malignancy with 2 main subgroups — classical and nodular lymphocyte predominant — which are distinguished by cellular morphology and immunophenotype.1 Treatment for classical HL is determined after staging, which is performed using the ...

“These findings are the culmination of two decades of research at NCI and elsewhere, advancing our understanding of the effect of DNA mutations and gene expression on lymphoma biology and outcome,” said NCI Director Ned Sharpless, MD in a press release. “This refined molecular classification will ...

The U.S. Food and Drug Administration (FDA) will review an application requesting duvelisib's full approval for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and accelerated approval for relapsed/refractory follicular lymphoma (FL). The new drug ...

According to studies, breast implants have helped many women gain back their self-esteem and have a feeling of satisfaction. Breast implants bring positive effects on women who once had lost their confidence, but women should also be aware of what breast implants are being attributed to that can result ...

... preclinical activity against EZH2-mutant non-Hodgkin lymphomas, INI1-negative rhabdoid tumors, and SMARCA4-negative rhabdoid tumors of the ovary. For this phase 1 study (ClinicalTrials.gov Identifier: NCT01897571), researchers enrolled patients with relapsed/refractory non-Hodgkin lymphoma or ...

The FDA has granted a priority review to a new drug application (NDA) for duvelisib for a full approval for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and an accelerated approval for the treatment of patients with relapsed/refractory ...

There is the use of maintenance rituximab following bendamustine/rituximab (BR) induction therapy. Though there are no clinical trials that are randomized to support this approach, there were some retrospective studies and analyses of prior follicular lymphoma cohorts that suggest a similar PFS benefit.

ORLANDO, Fla. (WOFL-Fox35) -- Keishla Betancourt's life in Puerto Rico was already in danger when Hurricane Maria struck. The 23 year old is battling Hodgkin's lymphoma, and doctors said she had only two weeks to live. “A clot that was going up very fast and was going to hit my heart in two weeks.

Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869-881. Twa DD, Chan FC, Ben-Neriah S, et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood. 2014 ...

He, from there, was referred to a surgeon who did a biopsy of one of the lymph nodes, which revealed grade 2 follicular lymphoma, and was referred from there to a hematologist who saw the cytopenias and did a bone marrow biopsy, which also found involvement of follicular lymphoma in the bone marrow ...

FDA approvals in chronic myeloid leukemia and Hodgkin lymphoma, a priority review designation in colorectal cancer, a breakthrough therapy designation in urothelial carcinoma, a rolling new drug application completed in TRK-fusion cancers, and promising phase III findings in a lung cancer trial.

Certain quantitative PET parameters can help clinicians predict how well patients with Hodgkin's lymphoma will react to their treatment, according to preliminary results from a study conducted in the Ukraine and presented at ECR 2018 in Vienna. In a comparison of several variables, the researchers found ...

And in that clinical trial, a group of physicians around the country treated people with rituximab- and alkylator-refractory follicular lymphoma. So, in other words, we treated a group of patients who were probably more resistant to therapy than this patient, where they had to have relapsed within 6 months of ...

Patients included in the study had asymptomatic follicular lymphoma and were deciding between active treatment utilizing rituximab or watchful waiting. If a patient experienced a relapse after active treatment, then he or she would be given another chemotherapy regimen with or without rituximab or an ...

TTI-621, an investigational molecule developed by Trillium that turns macrophages against tumor cells, was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of cutaneous T-cell lymphoma. The designation aims to encourage therapies for rare and serious diseases by ...

The US Food and Drug Administration has approved Adcetris (brentuximab vedotin) to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. “Today's approval represents an improvement in the initial treatment regimens of ...

Voxtalisib, an investigational agent that targets both mammalian target of rapamycin (mTOR) and multiple isoforms of phosphoinositide-3 kinase (PI3K), showed “promising” efficacy with acceptable safety in patients with relapsed or refractory follicular lymphoma, results of a phase 2 trial indicate. Among 46 ...

The FDA has approved brentuximab vedotin (Adcetris, Seattle Genetics, Inc.) in combination with chemotherapy in adult patients with previously untreated stage III or IV classical Hodgkin's lymphoma. The approval is based on the successful outcome of the phase 3 ECHELON-1 clinical trial that compared ...

The disease is not breast cancer but is a malignancy of the immune system called breast-implant-associated anaplastic large-cell lymphoma. When detected early, it can usually be cured by surgery alone, by removing the implant and the capsule of scar tissue that forms around it. But some women have ...

One of the driving forces behind non-Hodgkin lymphomas is the over-activation of a receptor on the surface of B cells. This receptor normally stimulates the growth of B-cells only when it is needed, but in non-Hodgkin lymphoma, the growth signal is constantly on, making B-cells grow uncontrollably.

The disease is not breast cancer, but is a malignancy of the immune system called breast implant-associated anaplastic large-cell lymphoma. When detected early, it can usually be cured by surgery alone, by removing the implant and the capsule of scar tissue that forms around it. But some women have ...

The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy as a frontline treatment for adult patients with stage III or IV classical Hodgkin lymphoma, according to a statement from Seattle Genetics, the manufacturer of the CD30-targeted antibody-drug conjugate.